TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32310854
Drug: Subcutaneous insulin
Normalized name: subcutaneous insulin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous insulin therapy only
Study: 32310854
Drug: Oral vildagliptin
Normalized name: vildagliptin
DrugBank: Vildagliptin (DB04876)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Oral vildagliptin plus subcutaneous insulin
Study: 33588077
Drug: Videoconference-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Videoconference-delivered cognitive behaviour therapy for insomnia (CBT-I)
Study: 33460256
Drug: Intensive blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive blood pressure treatment (SBP < 120 mm Hg)
Study: 33460256
Drug: Standard blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard blood pressure treatment (SBP < 140 mm Hg)
Study: 32009299
Drug: Topical TFB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical TFB application
Study: 32084526
Drug: Liver-directed concurrent
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liver-directed concurrent chemoradiotherapy (LD-CCRT) and sequential sorafenib treatment (400 mg, twice daily)
Study: 35289183
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (200 mg/kg) administered intravenously for 30 minutes after return of spontaneous circulation
Study: 34266522
Drug: Lactase treatment
Normalized name: Lactase
DrugBank: Tilactase (DB13761)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactase treatment (4 drops of lactase additive, 180 mg added into preterm formula or breast milk)
Study: 34266522
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (placebo, oral probiotics at half an hour after feeding, and abdominal massage)
Study: 34366180
Drug: Digital media-based
Normalized name: Stellaria media extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital media-based hand therapy (self-directed, 12-week protocol)
Study: 34366180
Drug: Traditional hand
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional hand therapy (12-week protocol)
Study: 34828790
Drug: Combined Music
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Music Therapy (MT) and Skin-to-Skin Care (SSC)
Study: 33839489
Drug: Nasal betamethasone
Normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nasal betamethasone drops (3 times daily for a maximum of one month)
Study: 33839489
Drug: Placebo (9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (9% NaCl drops, similar dosage to betamethasone)
Study: 32911009
Drug: SDA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: SDA treatment using resin bonded bridgework (RBB)
Study: 35723714
Drug: Adjunctive botanical
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjunctive botanical patch applications (3 times on day 0 and once daily on days 1-6)
Study: 35723714
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional therapy (SRP alone, control)
Study: 35723714
Drug: Adjunctive botanical
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adjunctive botanical patch applications
Study: 36053757
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg MTX subcutaneously
Study: 36053757
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg MTX orally
Study: 36053757
Drug: MJK101 (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: MJK101 (subcutaneous MTX)
Study: 36030801
Drug: Midwife group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midwife group (sublingual misoprostol 400 μg every 3 hours for up to five doses)
Study: 36030801
Drug: Physician group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physician group (sublingual misoprostol 400 μg every 3 hours for up to five doses)
Study: 36345347
Drug: Intravenous sildenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sildenafil dosed every 8 hours for up to 34 days at doses of 0.125, 0.5, and 1 mg/kg/dose in cohorts 1, 2, and 3, respectively.
Study: 36345347
Drug: Enteral sildenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral sildenafil dosed every 8 hours for up to 34 days at doses double the IV doses.
Study: 35815354
Drug: BFF MDI
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BFF MDI (budesonide/formoterol fumarate dihydrate metered dose inhaler) 320/10 µg with a spacer
Study: 35815354
Drug: BUD/FORM DPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUD/FORM DPI (budesonide/formoterol fumarate dry powder inhaler) 320/9 µg
Study: 33778945
Drug: 36 or
Normalized name: pediatric multivitamin no.136 ORAL TABLET,CHEWABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 36 or 54 mg of extended-release methylphenidate
Study: 33933265
Drug: Autologous platelet
Normalized name: AUTOLOGOUS PLATELET RICH PLASMA
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous platelet gel application in tubularized incised plate (TIP) repair
Study: 33933265
Drug: TIP repair
Normalized name: hyaluronic acid Ophthalmic Gel [Optimend Corneal Repair]
Approvals — FDA: no, EMA: no, PMDA: no
Description: TIP repair without autologous platelet gel
Study: 35830848
Drug: Cinnamon infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnamon infusion (2 g, Cinnamomum sp.)
Study: 32212012
Drug: Subcutaneous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous heparin at a prophylactic dose (SHPD) - enoxaparin 4000 U/day
Study: 32212012
Drug: SHPD reduction/discontinuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHPD reduction/discontinuation
Study: 34312872
Drug: Early orthodontic
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early orthodontic therapy (OT) at 4 weeks post surgery
Study: 34312872
Drug: Late orthodontic
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late orthodontic therapy (OT) at 6 months post surgery
Study: 34312872
Drug: Early orthodontic
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early orthodontic therapy (OT)
Study: 34312872
Drug: Late orthodontic
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late orthodontic therapy (OT)
Study: 35192411
Drug: Selumetinib 75
Normalized name: Sélumétinib
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selumetinib 75 mg orally twice daily for approximately 5 weeks
Study: 33522954
Drug: Healthy low-carbohydrate
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy low-carbohydrate diet (< 40 g of net carbohydrates for the first 3 months and < 40 to 60 net grams for months 3 to 6)
Study: 35575839
Drug: 8-week distance-delivered
Normalized name: CISTANCHE TINCTORIA STEM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-week distance-delivered social skills program, sessions offered twice a week for 90 min
Study: 33150640
Drug: Cognitive Behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavior Therapy (CBT‐E)
Study: 35688173
Drug: Nivolumab (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (240 mg IV every 2 weeks) plus Cabozantinib (40 mg orally once daily)
Study: 35688173
Drug: Sunitinib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib (50 mg orally once daily)
Study: 34331676
Drug: Probiotics used
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics used concurrently with antibiotics (Bifidobacterium longum, Lactobacillus acidophilus, and Enterococcus faecalis) for 1 week
Study: 34331676
Drug: Probiotics used
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics used after antibiotics for 1 week
Study: 34331676
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment (piperacillin–tazobactam) for 1 week
Study: 34331676
Drug: No intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intervention (antibiotic therapy only)
Study: 32727497
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (weekly cisplatin with IMRT)
Study: 35086790
Drug: OligoG (1050
Approvals — FDA: no, EMA: no, PMDA: no
Description: OligoG (1050 mg daily)
Study: 32723265
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy and an oral integrator (Micronil Dol®) composed of acetyl‐L‐carnitine, α‐lipoic acid, quercetin, bromelain, pantothenic acid, C and B1 and B2 and B6 and B12 vitamins
Study: 34424730
Drug: Weekly rifapentine‐isoniazid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly rifapentine‐isoniazid for 3 months (n=3610)
Study: 34424730
Drug: Daily isoniazid
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily isoniazid for 6 months (n=404)
Study: 32773581
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg of aspirin daily during pregnancy
Study: 32773581
Drug: Placebo daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily during pregnancy
Study: 39300222
Drug: Ibrutinib 420
Normalized name: ibrutinib 420 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib 420 mg/day
Study: 32326796
Drug: Ticagrelor (aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (aspirin plus ticagrelor)
Study: 32326796
Drug: Clopidogrel (aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (aspirin plus clopidogrel)
Study: 34259404
Drug: Auricular intradermal
Normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular intradermal needling
Study: 35671038
Drug: Tralokinumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tralokinumab (300 mg) administered subcutaneously every 2 weeks
Study: 38631826
Drug: Aspirin 150
Normalized name: aspirin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 150 mg daily
Study: 35958552
Drug: Low-dose rituximab
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose rituximab (600 mg)
Study: 34174084
Drug: Flexible and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexible and pragmatic approaches (e.g., interviews instead of focus groups)
Study: 34916086
Drug: Apalutamide 240
Normalized name: apalutamide 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apalutamide 240 mg/d
Study: 34654929
Drug: Drug arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug arm
Study: 35500786
Drug: High dose-rate
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose-rate brachytherapy (HDR) monotherapy
Study: 35500786
Drug: High dose-rate
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose-rate brachytherapy (HDR) boost
Study: 35469481
Drug: Mepivacaine injection
Normalized name: mepivacaine Injection
DrugBank: Mepivacaine (DB00961)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mepivacaine injection into the temporalis tendon
Study: 35469481
Drug: Nerve growth
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerve growth factor injection into the temporalis tendon
Study: 35469481
Drug: Nerve growth
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerve growth factor injection
Study: 32155399
Drug: Inadequate adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inadequate adjuvant treatment
Study: 33631357
Drug: Ramipril 2.5
Normalized name: ramipril 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 2.5 mg orally daily for 14 days
Study: 32363556
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (10,000 IU twice weekly) combined with clomiphene citrate (50 mg twice daily for 5 days)
Study: 32363556
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with calcium (1250 mg twice daily) combined with clomiphene citrate (50 mg twice daily for 5 days)
Study: 34062587
Drug: Betalactam-antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betalactam-antibiotics
Study: 34062587
Drug: Post-treatment patients
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment patients
Study: 34468794
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E (400 mg twice daily)
Study: 33407490
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose walnut (30 g/d)
Study: 33407490
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose walnut (60 g/d)
Study: 33407490
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (low dose, high dose, control)
Study: 32192623
Drug: Bupropion therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion therapy along with standard counselling
Study: 34714969
Drug: Abelacimab (30-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abelacimab (30-150 mg) intravenous single doses
Study: 34714969
Drug: Abelacimab (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abelacimab (120 mg and 180 mg) subcutaneous monthly doses
Study: 34714969
Drug: Abelacimab (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abelacimab (intravenous and subcutaneous)
Study: 36432401
Drug: Dietary prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary prescription with nutritional recommendations, nutritional education program based on playful strategies, suggestions of typical and accessible Brazilian foods and intensive monitoring
Study: 32945627
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (daily dosage not specified) for 6 months
Study: 32710585
Drug: Herbal cream
Normalized name: Hyperici herba
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herbal cream (cream A) applied topically twice-daily
Study: 32710585
Drug: Control cream
Normalized name: BENZOYL PEROXIDE 3 mg in 60 mL TOPICAL LIQUID [Acnecare Dermacontrol Cream]
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control cream (cream B) applied topically twice-daily
Study: 33879077
Drug: Eculizumab (resumed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eculizumab (resumed recommended dose after trial of weaning)
Study: 33879077
Drug: Eculizumab (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eculizumab (initial treatment)
Study: 33436973
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (ICS) use
Study: 34259400
Drug: Combination group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination group (tapping at acupoints along meridian + thunder-fire moxibustion)
Study: 34259400
Drug: Routine group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine group (routine treatment and nursing)
Study: 33469679
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of OVV-Beclin1 and R-CHOP
Study: 38168442
Drug: 5% 5-Fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% 5-Fluorouracil (5-FU) cream
Study: 33858561
Drug: Arsenic trioxide
Normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Arsenic trioxide (ATO) combined with chemotherapy
Study: 36177741
Drug: metronidazole gel
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: metronidazole gel (0.75%)
Study: 34218516
Drug: Guided Biofilm
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Guided Biofilm Therapy (GBT) using erythritol powder (AIRFLOW®)
Study: 35197363
Drug: JAK inhibitors
Normalized name: Janus-associated kinase (JAK) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: JAK inhibitors
Study: 32994251
Drug: 0.145% fluoride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.145% fluoride gel applied using custom trays after brushing every night while sleeping
Study: 32994251
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene instructions as usual
Study: 33650454
Drug: Euglycemic no-insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Euglycemic no-insulin cohort (ENo-I, n = 111)
Study: 35330828
Drug: Dexmedetomidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1 μg/kg in 10 min) followed by a constant infusion rate (0.5 μg kg−1 h−1) (D2 group)
Study: 35330828
Drug: Dexmedetomidine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine at a constant infusion rate (0.5 μg kg−1 h−1) (D1 group)
Study: 35330828
Drug: Propofol- and
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol- and remifentanil-based total intravenous anesthesia (T group)
Study: 36416665
Drug: Automated Oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated Oxygen Administration (AOA)
Study: 33331859
Drug: Ranibizumab 0.5
Normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 0.5 mg and 2.0 mg, administered monthly or on an as-needed basis over 24 months
Study: 32237012
Drug: High-dose spironolactone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose spironolactone (100 mg daily)
Study: 35637354
Drug: Neck stretching
Normalized name: Mederma Stretch Mark Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neck stretching and movement exercises three times daily for four weeks post-surgery
Study: 33279389
Drug: High-dose dabigatran
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose dabigatran (150 mg bid), rivaroxaban, high-dose edoxaban (60 mg daily)
Study: 33279389
Drug: Antiplatelet treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet treatment with aspirin and P2Y12 receptor antagonists
Study: 33279389
Drug: DOACs (Direct
Approvals — FDA: no, EMA: no, PMDA: no
Description: DOACs (Direct Oral Anticoagulants)
Study: 35137572
Drug: Treatment satisfaction
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment satisfaction questionnaire
Study: 35112931
Drug: BH4 (≈10
Approvals — FDA: no, EMA: no, PMDA: no
Description: BH4 (≈10 mg/kg, post)
Study: 32050789
Drug: Ultrasound-guided subcostal
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided subcostal transversus abdominis plane (TAP) block with 30 mL local anesthetic (20 mL bupivacaine 0.125% plus 10 mL lidocaine 1%)
Study: 32050789
Drug: IV analgesic
Normalized name: ANALGESIC CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV analgesic management with paracetamol 1 g
Study: 33579199
Drug: Dexamethasone group
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone group (8 mg dexamethasone with 0.375% ropivacaine)
Study: 32667287
Drug: Argatroban treatment
Normalized name: Argatroban
DrugBank: Argatroban (DB00278)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Argatroban treatment
Study: 33998024
Drug: Supportive periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive periodontal therapy visits (SPT) with regularity
Study: 33998024
Drug: Supportive periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive periodontal therapy visits (SPT) with irregularity
Study: 33998024
Drug: Supportive periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive periodontal therapy visits (SPT)
Study: 35040869
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E supplementation (vitE), dosage not specified, duration 3 years (baseline to year 3)
Study: 33333334
Drug: Direct oral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct oral anticoagulants (apixaban, dabigatran, edoxaban, rivaroxaban)
Study: 33333334
Drug: Twice-daily regimen
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily regimen of direct oral anticoagulants
Study: 33461323
Drug: Corticosteroid (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid (40 mg methylprednisolone)
Study: 33057367
Drug: Higher sTFR
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher sTFR or iron stores, the HFE 187C>G variant, and lower baseline hsCRP
Study: 33852200
Drug: PRM 6
Normalized name: Pramipexole
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PRM 6 mg/day
Study: 33852200
Drug: Low-dose PRM
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose PRM
Study: 33852200
Drug: Higher-dose PRM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-dose PRM
Study: 36309647
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of intermediate radiologist with LR radiomic model
Study: 35721014
Drug: Real continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real continuous theta burst stimulation (cTBS) over the right cerebellar Crus I + 30-min speech-language therapy